Financials
By Ikaba Koyi
Date: Tuesday 21 Nov 2017
LONDON (ShareCast) - (ShareCast News) - NetScientific, the transatlantic healthcare IP commercialisation group, has today announced that ProAxsis, its portfolio company in which it holds a 57% stake, is forecasting higher direct sales of its ProteaseTag Active Neutrophil Elastase Immunoassay.
ProAxsis said it expected its NEIA sales to increase three-fold in the second half of 2017 versus the first six months of the year with total revenue expected to surpass £1m in 2018.
Commenting on the news, Francois Martelet, chief executive officer of NetScientific and Chairman of ProAxsis, said: "We are pleased to see signs of rapid market adoption of the CE marked NEIA test which uses ProAxsis' market leading ProteaseTag® technology. We are especially encouraged to see the acceleration of sales through a combination of repeat orders and new customers from leading research institutions across Europe and the US. We expect 2018 to be a pivotal year for ProAxsis with further planned product launches and potential industry partnerships as value inflection points."
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 63.00p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 80.50 |
52 Week Low | 49.00 |
Volume | 904 |
Shares Issued | 23.95m |
Market Cap | £15.09m |
RiskGrade | 410 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
10:08 | 650 @ 61.00p |
08:20 | 254 @ 61.40p |
CEO | Ilian Iliev |
CFO | Stephen Crowe |
You are here: research